Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by Stockspawkon Sep 25, 2018 8:43am

216 Views

Post# 28683931

RE:RE:RE:RE:RE:sales projection?

Yup. Very good sognal that insiders are buying. 6 decent size transactions in the latter part of this month.

Sep 24/18	Sep 24/18	McMillan, Michael	Direct Ownership	Common Shares	10 - Acquisition in the public market	100,000	$0.308
Sep 20/18	Sep 19/18	Wallace, John Lawrence	Direct Ownership	Common Shares	10 - Acquisition in the public market	100,000	$0.270
Sep 19/18	Sep 19/18	Legault, Daniel Marcel	Direct Ownership	Common Shares	10 - Acquisition in the public market	100,000	$0.260
Sep 19/18	Sep 19/18	Wilson, Alain	Control or Direction	Common Shares	10 - Acquisition in the public market	35,000	$0.270
Sep 19/18	Sep 18/18	Curtis, Scott Wilson	Direct Ownership	Common Shares	10 - Acquisition in the public market	50,000	$0.260
Sep 18/18	Sep 18/18	Bourgeois, Nicolas	Direct Ownership	Common Shares	10 - Acquisition in the public market	100,000	$0.262